1. < Home

non-small-cell lung cancer

Dendritic Cell Vaccination in Non-Small Cell Lung Cancer: Remodeling the Tumor Immune Microenvironment

Abascal J, Oh MS, Liclican EL, Dubinett SM, Salehi-Rad R, Liu B. Dendritic Cell Vaccination in Non-Small Cell Lung Cancer: Remodeling the Tumor Immune Microenvironment.[...]

By sjmartinez • October 14, 2023
Bintrafusp alfa with cCRT followed by bintrafusp alfa versus placebo with cCRT followed by durvalumab in patients with unresectable stage III NSCLC: A phase 2 randomized study

Vokes EE, Mornex F, Sezer A, Cheng Y, Fang J, Baz DV, Cil T, Adjei AA, Ahn MJ, Barlesi F, Felip E, Garon EB, Audhuy[...]

By sjmartinez • October 6, 2023
A phase Ib/II dose expansion study of subcutaneous sasanlimab in patients with locally advanced or metastatic non-small-cell lung cancer and urothelial carcinoma

Cho BC, Penkov K, Bondarenko I, Kurochkin A, Pikiel J, Ahn HK, Korożan ME, Osipov M, Odintsova S, Braiteh F, Ribas A, Grilley-Olson JE, Lugowska[...]

By sjmartinez • June 30, 2023
Real-world adjuvant chemotherapy patterns and outcomes among elderly patients with resected early non-small-cell lung cancer in the USA

Lee JM, Wang R, Johnson A, Ogale S, Kent M, Lee JS. Real-world adjuvant chemotherapy patterns and outcomes among elderly patients with resected early non-small-cell[...]

By sjmartinez • March 29, 2023
LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIA RET fusion-positive non-small-cell lung cancer

Tsuboi M, Goldman JW, Wu YL, Johnson ML, Paz-Ares L, Yang JC, Besse B, Su W, Chao BH, Drilon A. LIBRETTO-432, a phase III study[...]

By sjmartinez • August 11, 2022